Targeting the translation machinery in cancer
Cet article passe en revue les perspectives offertes par les travaux récents sur le rôle des mécanismes de traduction génétique dans les cellules cancéreuses pour le développement de nouveaux traitements, notamment pour la prise en compte de l'hétérogénéité intratumorale
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.